Yüklüyor......
Current state of immunotherapy for non-small cell lung cancer
Lung cancer is the leading cause of cancer mortality and non-small cell lung cancer (NSCLC) accounts for more than 85% of all lung cancers. Platinum-based doublet chemotherapy is the standard first-line treatment for metastatic NSCLC when genomic testing reveals no targetable alteration such as epid...
Kaydedildi:
| Yayımlandı: | Transl Lung Cancer Res |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
AME Publishing Company
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5420529/ https://ncbi.nlm.nih.gov/pubmed/28529902 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2017.03.01 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|